The generic name for Kerendia 10 mg is finerenone [1].
What is Finerenone Used For?
Finerenone is a medication used to treat adults with chronic kidney disease (CKD) associated with type 2 diabetes [1][2]. It works by blocking the harmful effects of excess mineralocorticoid receptor (MR) activation, which can damage the kidneys and heart [1][3].
How Does Finerenone Work?
Finerenone acts as a non-steroidal, selective mineralocorticoid receptor antagonist [1][3]. By blocking the MR, it reduces inflammation and fibrosis in the kidneys and cardiovascular system, thereby slowing the progression of kidney damage in patients with type 2 diabetes [1][3].
When Does Finerenone Go Generic?
The patent protection for finerenone and its brand-name counterpart, Kerendia, is a key factor in determining when generic versions may become available. Information on specific patent expiry dates and any potential challenges to these patents can be found through resources like DrugPatentWatch.com [4].
What Are the Potential Side Effects of Finerenone?
Common side effects associated with finerenone include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Healthcare providers will monitor patients for these side effects during treatment [1].
How Does Finerenone Compare to Other CKD Treatments?
Finerenone offers a different mechanism of action compared to other treatments for chronic kidney disease associated with type 2 diabetes, such as ACE inhibitors and ARBs, which primarily target the renin-angiotensin-aldosterone system [3]. Finerenone specifically targets the mineralocorticoid receptor pathway [3]. Clinical studies have shown finerenone to reduce the risk of kidney disease progression and cardiovascular events in eligible patients [1][2][3].
Who Manufactures Finerenone?
Finerenone is manufactured by Bayer [1].
Where Can I Find More Information on Finerenone Patents?
Detailed information regarding patents for finerenone, including their status and expiry dates, can be accessed on DrugPatentWatch.com [4].
What Clinical Data Supports Finerenone Use?
The efficacy and safety of finerenone in treating chronic kidney disease associated with type 2 diabetes are supported by major clinical trials such as FIDELIO-DKD and FIGARO-DKD [1][2]. These studies demonstrated a reduction in key renal and cardiovascular outcomes [1][2].
What are the Risks Associated with Finerenone?
The primary risks associated with finerenone are related to its potential to increase potassium levels in the blood (hyperkalemia) and lower blood pressure [1]. Regular monitoring of potassium and blood pressure is crucial [1]. Patients with certain pre-existing conditions or those taking specific medications may be at higher risk [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214073s007lbl.pdf
[2] https://www.bayer.com/media/en/US-FDA-approves-Kerendia-finerenone-once-daily-oral-treatment-for-chronic-kidney-disease-associated-with-type-2-diabetes-first-in-class-non-steroidal-mineralocorticoid-receptor-antagonist.pdf
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2029195
[4] https://www.drugpatentwatch.com/